NCT07145918View on ClinicalTrials.gov

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Schizophrenia
Interventions
DRUG

Emraclidine

Oral Tablets

DRUG

Placebo

Oral Tablets

Trial Locations (5)

72211

RECRUITING

Woodland International Research Group /ID# 275747, Little Rock

75080

RECRUITING

Pillar Clinical Research - Richardson /ID# 275715, Richardson

78754

RECRUITING

Community Clinical Research - Austin - Cross Park Drive /ID# 272977, Austin

92845

RECRUITING

Collaborative Neuroscience Research - Garden Grove /ID# 273005, Garden Grove

08053

RECRUITING

Cenexel Hassman Research Institute (Hri) /ID# 276128, Marlton

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY